LTFS
LGND icon

Ladenburg Thalmann Financial Services’s Ligand Pharmaceuticals LGND Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$232K Buy
3,549
+1,823
+106% +$122K ﹤0.01% 2391
2019
Q3 		$107K Buy
1,726
+412
+31% +$25.9K ﹤0.01% 2884
2019
Q2 		$95K Buy
1,314
+250
+23% +$18.4K ﹤0.01% 3004
2019
Q1 		$84K Buy
1,064
+61
+6% +$4.62K ﹤0.01% 3011
2018
Q4 		$84K Buy
1,003
+668
+199% +$71.2K ﹤0.01% 2875
2018
Q3 		$58K Sell
335
-438
-57% -$66K ﹤0.01% 3208
2018
Q2 		$79K Hold
773
– – ﹤0.01% 2920
2018
Q1 		$79K Sell
773
-1
-0.1% -$99 ﹤0.01% 2920
2017
Q4 		$67K Buy
774
+107
+16% +$9.27K ﹤0.01% 3023
2017
Q3 		$57K Sell
667
-67
-9% -$5.3K ﹤0.01% 2993
2017
Q2 		$56K Sell
734
-63
-8% -$4.41K ﹤0.01% 2944
2017
Q1 		$53K Buy
797
+10
+1% +$658 ﹤0.01% 2860
2016
Q4 		$51K Buy
787
+141
+22% +$8.9K ﹤0.01% 2833
2016
Q3 		$42K Sell
646
-1,015
-61% -$74.5K ﹤0.01% 2908
2016
Q2 		$125K Buy
1,661
+874
+111% +$64.9K ﹤0.01% 1994
2016
Q1 		$53K Sell
787
-451
-36% -$27.4K ﹤0.01% 2551
2015
Q4 		$84K Sell
1,238
-5,775
-82% -$357K ﹤0.01% 2188
2015
Q3 		$374K Buy
7,013
+2,366
+51% +$144K 0.01% 1120
2015
Q2 		$293K Buy
4,647
+3,897
+520% +$213K 0.01% 1350
2015
Q1 		$36K Buy
750
+195
+35% +$7.47K ﹤0.01% 2799
2014
Q4 		$18K Sell
555
-596
-52% -$19.4K ﹤0.01% 3057
2014
Q3 		$34K Buy
1,151
+1,122
+3,869% +$37.2K ﹤0.01% 2271
2014
Q2 		$1K Buy
+29
New +$1.18K ﹤0.01% 3765
2014
Q1 		– Sell
-321
Closed -$11K – 3807
2013
Q4 		$11K Buy
+321
New +$10.5K ﹤0.01% 2883

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Ladenburg Thalmann Financial Services's LGND Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Ligand Pharmaceuticals (LGND) stake by 106% in Q4 2019, buying an estimated $122K and bringing the position to 3,549 shares worth $232K. The position accounts for ﹤0.01% of the portfolio, ranked #2391.

Ladenburg Thalmann Financial Services first reported a position in LGND in Q4 2013 and has held it in 24 quarters since. The position peaked at $374K in Q3 2015. 266 funds tracked by Wall St. Rank hold LGND as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 3,549 shares of Ligand Pharmaceuticals worth $232K as of Q4 2019.
  • Ladenburg Thalmann Financial Services bought 1,823 Ligand Pharmaceuticals shares in Q4 2019, an estimated $122K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #2391 holding.
  • Ladenburg Thalmann Financial Services first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 24 quarters since.
  • Ladenburg Thalmann Financial Services's Ligand Pharmaceuticals position peaked at $374K in Q3 2015.
  • 266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.